Department of Anesthesia, Critical Care and Emergency, Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico, Via F. Sforza 35, 20122, Milan, MI, Italy.
Department of Biomedical, Surgical and Dental Sciences, University of Milan, Milan, MI, Italy.
J Nephrol. 2022 Sep;35(7):1885-1893. doi: 10.1007/s40620-022-01392-z. Epub 2022 Jul 15.
The clinical trajectory of post-operative acute kidney injury (AKI) following lung transplantation for cystic fibrosis is unknown.
Incidence and risk factors for post-operative AKI, acute kidney disease (AKD) and chronic kidney disease (CKD) were retrospectively analyzed in cystic fibrosis patients undergoing lung transplantation. Logistic regressions, Chi-square, Cuzick rank tests, and Cox-proportional hazard models were used.
Eighty-three patients were included. Creatinine peaked 3[2-4] days after transplantation, with 15(18%), 15(18%), and 20(24%) patients having post-operative AKI stages 1, 2, and 3, while 15(18%), 19(23%) and 10(12%) developed AKD stage 1, stage 2 and 3, respectively. Higher AKI stage was associated with worsening AKD (p = 0.009) and CKD (p = 0.015) stages. Of the 50 patients with AKI, 32(66%) transitioned to AKD stage > 0, and then 27 (56%) to CKD stage > 1. Female sex, extracorporeal membrane oxygenation support as a bridge to lung transplant and at the end of the surgery, the use of intraoperative blood components, and cold-ischemia time were associated with increased risk of post-operative AKI and AKD. Higher AKI stage prolonged invasive mechanical ventilation (p = 0.0001), ICU stay (p = 0.0001), and hospital stay (p = 0.0001), and increased the incidence of primary graft dysfunction (p = 0.035). Both AKI and AKD stages > 2 worsened long-term survival with risk ratios of 3.71 (1.34-10.2), p = 0.0131 and 2.65(1.02-6.87), p = 0.0443, respectively.
AKI is frequent in cystic fibrosis patients undergoing lung transplantation, it often evolves to AKD and to chronic kidney disease, thereby worsening short- and long-term outcomes.
囊性纤维化患者肺移植术后急性肾损伤(AKI)的临床病程尚不清楚。
回顾性分析了接受肺移植的囊性纤维化患者术后 AKI、急性肾疾病(AKD)和慢性肾脏病(CKD)的发生率和危险因素。使用逻辑回归、卡方检验、Cuzick 等级检验和 Cox 比例风险模型。
83 例患者入组。术后肌酐峰值出现在移植后 3[2-4]天,15(18%)、15(18%)和 20(24%)例患者分别出现术后 AKI 1 期、2 期和 3 期,而 15(18%)、19(23%)和 10(12%)例患者分别出现 AKD 1 期、2 期和 3 期。较高的 AKI 分期与 AKD(p=0.009)和 CKD(p=0.015)分期的恶化相关。在 50 例 AKI 患者中,32(66%)进展为 AKD 期>0,然后 27(56%)进展为 CKD 期>1。女性、体外膜氧合作为肺移植的桥接支持、手术结束时、术中使用血液成分和冷缺血时间与术后 AKI 和 AKD 的风险增加相关。较高的 AKI 分期延长了有创机械通气(p=0.0001)、ICU 住院时间(p=0.0001)和住院时间(p=0.0001),并增加了原发性移植物功能障碍的发生率(p=0.035)。AKI 和 AKD 期>2 均使长期生存率恶化,风险比分别为 3.71(1.34-10.2),p=0.0131 和 2.65(1.02-6.87),p=0.0443。
AKI 在接受肺移植的囊性纤维化患者中很常见,它经常进展为 AKD 和慢性肾脏病,从而恶化短期和长期预后。